Risk factors and outcomes of bloodstream infections with metallo-beta-lactamase-producing Acinetobacter

Scand J Infect Dis. 2008;40(3):234-40. doi: 10.1080/00365540701633004. Epub 2007 Sep 7.

Abstract

The spread of Gram-negative bacilli with acquired metallo-beta-lactamase (MBL) threatens the successful treatment of major nosocomial infections. The objective of this study was to evaluate the differences in the clinical characteristics of bacteremia caused by MBL-producing Acinetobacter species and MBL non-producing isolates. Two retrospective case-control studies were conducted using data on patients with Acinetobacter bacteremia, who were admitted between January 2001 and December 2005 at a 1500-bed, tertiary-care teaching hospital. Case group 1 (n=27) included patients from whom imipenem-resistant Acinetobacter was isolated in blood culture, and case group 2 (n=7) consisted of those patients from group 1 who yielded MBL-producing isolates. The control group (n=41) included patients from whom carbapenem-susceptible Acinetobacter isolates were isolated in blood culture. Multivariate analysis revealed that the independent risk factors for imipenem-resistant Acinetobacter bacteremia were neutropenia and prolonged use of carbapenem. The independent risk factors for MBL-producing Acinetobacter bacteremia were neutropenia and prolonged use of cephalosporins. The results of this study suggest that a prolonged use of cephalosporins may be associated with MBL-producing Acinetobacter bacteremia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter / classification
  • Acinetobacter / drug effects*
  • Acinetobacter / enzymology
  • Acinetobacter / isolation & purification
  • Acinetobacter Infections / drug therapy
  • Acinetobacter Infections / epidemiology
  • Acinetobacter Infections / microbiology*
  • Acinetobacter Infections / physiopathology
  • Adult
  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteremia / epidemiology
  • Bacteremia / microbiology*
  • Bacteremia / physiopathology
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Case-Control Studies
  • Cephalosporins / pharmacology
  • Cephalosporins / therapeutic use
  • DNA Fingerprinting
  • DNA, Bacterial / genetics
  • Drug Resistance, Bacterial*
  • Electrophoresis, Gel, Pulsed-Field
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neutropenia / complications
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • beta-Lactamases / biosynthesis*

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Cephalosporins
  • DNA, Bacterial
  • beta-Lactamases